Amcinonide label

Amcinonide

Amcinonide Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

History

There is currently no drug history available for this drug.

Other Information

The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents.

TOPICAL CREAM USP, 0.1%

Each gram of Amcinonide Cream contains 1 mg of the active steroid amcinonide in a white, smooth, homogeneous, opaque emulsion composed of benzyl alcohol (as preservative), emulsifying wax, glycerin, isopropyl palmitate, lactic acid, purified water and sorbitol solution 70%.

TOPICAL OINTMENT USP, 0.1%

Each gram of Amcinonide Ointment contains 1 mg of the active steroid amcinonide in a specially formulated base composed of benzyl alcohol 2.2% (wt/wt) as preservative, butylated hydroxyanisole, citric acid anhydrous, emulsifying wax, propyl gallate, propylene glycol, and white petrolatum.

Chemically, amcinonide is:

Chemical Structure

Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-16,17-[cyclopentylidenebis (oxy)]-9-fluoro-11-hydroxy-, (11β, 16α).

Amcinonide Manufacturers

  • Taro Pharmaceuticals U.s.a., Inc.
    Amcinonide | Taro Pharmaceuticals U.s.a., Inc.
    No Recall

    Amcinonide | Taro Pharmaceuticals U.s.a., Inc.

    Amcinonide | Taro Pharmaceuticals U.s.a., Inc.

    Topical corticosteroids are generally applied to the affected area as a thin film from two to three times daily depending on the severity of the condition.

    Occlusive dressings may be a valuable therapeutic adjunct for the management of psoriasis or recalcitrant conditions.

    If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

  • E. Fougera & Co. A Division Of Fougera Pharmaceuticals Inc.
    Amcinonide | E. Fougera & Co. A Division Of Fougera Pharmaceuticals Inc.
    No Recall

    Amcinonide | E. Fougera & Co. A Division Of Fougera Pharmaceuticals Inc.

    Amcinonide | E. Fougera & Co. A Division Of Fougera Pharmaceuticals Inc.

    Topical corticosteroids are generally applied to the affected area as a thin film from two to three times daily depending on the severity of the condition.

    Occlusive dressings may be a valuable therapeutic adjunct for the management of psoriasis or recalcitrant conditions.

    If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.